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Abstract  Cystic  ﬁbrosis  (CF)  is  the  most  common  autosomal  recessive  disease  in  Caucasians.
Although  most  cases  are  diagnosed  in  childhood,  diagnosis  in  adults  is  apparently  increasing.
Objective:  Evaluate  the  adult  population  with  CF,  comparing  patients  who  were  diagnosed
before and  after  18  years  of  age.
Methods:  Retrospective  analysis  of  patients  followed  in  three  main  medical  centres  in  Portugal
in 2012.  Comparison  of  two  groups:  G1  --  patients  diagnosed  at  <18  years  and  G2  --  patients
diagnosed at  ≥18  years.
Results:  89  adults  were  identiﬁed:  61.8%  in  G1,  38.2%  in  G2.  Gender  distribution  was  simi-
lar in  both  groups.  Average  age  in  G2  was  higher  (38.3  ±  8.4  vs.  26.8  ±  6.1  years,  p  <  0.001).
Respiratory  symptoms  most  frequently  led  to  CF  diagnosis  in  all  patients,  mainly  in  adulthood.
There was  a  greater  percentage  of  patients  homozygous  for  the  mutation  delF508  in  G1  (43.6  vs.
8.8%, p  =  0.02).  Respiratory  and  pancreatic  function,  and  body  mass  index  (BMI)  showed  a  higher
severity  in  G1  (G1  vs.  G2:  FEV1:  54.6  ±  27.3  vs.  29.9  ±  64.6%,  p  =  0.177;  pancreatic  insufﬁciency
72.7 vs.  26.5%,  p  <  0.001;  BMI  20.2  ±  3.4  vs.  22.2  ±  4.8,  p  =  0.018).  Pseudomonas  aeruginosa  and
methicillin-sensitive  Staphylococcus  aureus  were  the  most  frequently  isolated  microorganisms.
Lung transplantation  rate  was  higher  in  G2  (20.6  vs.  10.9%,  p  =  0.231)  while  mortality  rate  was
higher in  G1  (0  vs.  3.6%,  p  =  0.261).  Hospital  admission  rate  was  higher  in  G1  as  well  as  mortality
rate.
Conclusion:  The  results  suggest  that  patients  with  CF  diagnosed  in  childhood  have  characteris-
tics that  distinguish  them  from  those  diagnosed  in  adulthood,  and  these  differences  may  have
implications  for  diagnosis,  prognosis  and  life  expectancy.sa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
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ystic  ﬁbrosis  (CF)  is  the  most  common  autosomal  recessive
isease  affecting  1  in  2500  newborns  among  Caucasians.1
Its  incidence  is  well  documented  in  Europe  where  1
n  2000--3000  newborns  are  affected.2 In  Portugal,  the
ncidence  is  apparently  lower  it  is  estimated  at  1:6000
ive  births.3 Currently,  however,  there  are  only  about  300
F  patients  (approximately  one-third  of  whom  are  adults)
n  follow-up  in  specialized  centres,  fewer  than  expected
onsidering  the  incidence  value  above.
The  gene  responsible  for  CF  encodes  a  protein  of
400  amino  acids,  which  functions  as  a  chloride-transport-
hannel  located  in  the  apical  epithelial  cells,  thereby
egulating  the  movement  of  solute  and  H2O.4--6 It  was
dentiﬁed  in  19897--9 and  since  then,  more  than  2000  disease-
ssociated  mutations  have  been  described.10
The  most  common  mutation,  which  is  termed  delF508
s  a  phenylalanine-residue  at  position  508  is  absent,  is
resent  in  approximately  70%  of  defective  cystic-ﬁbrosis-
ransmembrane-conductance-regulator  (CFTR)  alleles.10
CF  is  a  highly  variable  disease  and  patients  are  diagnosed
ith  different  presentations.  Symptoms  appear  in  the  ﬁrst
ear  of  life  in  the  great  majority  of  cases  but  may  appear
ater,  even  in  adulthood  with  considerable  variation  in  sever-
ty  and  rate  of  progression.4
The  gold-standard  laboratory  method  for  diagnosing  CF  is
he  sweat  test  but  there  are  other  methods  such  as  genetic
nalysis  or  the  determination  of  nasal  transepithelial  poten-
ial  difference.11,12 Since  2013  a  pilot  screening  programme
or  CF,  applied  to  all  newborns,  has  been  running  in  Portugal.
Patients  are  diagnosed  when  at  least  one  of  these  tests
ositive,  identiﬁcation  is  associated  with  one  or  more  pheno-
ypic  characteristics,  a  positive  neonatal  screening  or  family
istory.12
Although  CF  is  usually  discovered  early  in  life,  in  recent
ecades  it  is  no  longer  an  exclusively  paediatric  disease.
he  number  of  adults  with  CF  continues  to  increase,  while
he  number  of  children  has  remained  relatively  stable  over
he  past  decade.  In  2013,  adults  comprised  49.7%  of  the  CF
opulation,  compared  with  29.2%  in  1986.13 This  increase
ay  be  due  to  increased  survival,  secondary  to  effective
reatment,  more  diagnostic  capabilities  with  the  inclusion
f  milder  forms  of  the  disease,  greater  availability  and
mproved  genetic  testing,  using  more  speciﬁc  and  sensitive
iagnostic  criteria,  as  well  as  increased  sensitivity  to  the
ossibility  of  medical  diagnosis.14,15
The  ﬁrst  adult  CF  diagnosis  was  made  in  1946.16 Since
hat  time,  a  number  of  case  studies  of  adults  receiving  a
iagnosis  have  been  reported,  and  the  incidence  of  delayed
iagnosis  is  expected  to  increase.
There  are  a  number  of  reasons  for  diagnosis  as  adults.
irstly,  mild  expression  of  the  disease,  absent  symptoms  or
nusual  presentations  may  delay  a  patient  seeking  medical
ttention.17--19 Secondly,  the  common  perception  of  CF  as  a
isease  exclusive  to  childhood  leads  to  it  not  being  recog-
ized  in  adults,  especially  when  the  presenting  symptoms
re  atypical.20,21Please  cite  this  article  in  press  as:  Santo
http://dx.doi.org/10.1016/j.rppnen.2016.07.002
We  have  found  that  patients  presenting  in  adulthood
ppear  to  be  different  to  patients  presenting  in  childhood.
esearch  has  established  that,  as  a  group,  those  diagnosed
s  adults  have  variable  and  atypical  presentations,  and  often
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ave  milder  disease,22,23 better,  long-term  prognosis,23,24
etter  lung  function,  higher  rates  of  pancreatic  sufﬁciency,
ewer  complications,  and  longer  life  expectancy  than  adults
iagnosed  in  childhood.24--26
There  is  a growing  need  to  identify  differences  between
he  groups  but  there  are  no  published  data  in  Portugal.
The  objectives  of  this  study  were:  (1)  to  characterize
he  adult  CF  Portuguese  population,  comparing  patients  who
ere  diagnosed  before  and  after  18  years  of  age;  (2)  to
etermine  differences  between  the  two  groups  regarding
emographic  characteristics  and  variables  related  to  CF;
nd  (3)  to  investigate  potential  diagnostic  and  therapeutic
mplications  of  these  differences.
ethods
 retrospective  analysis  of  clinical  records  of  patients  fol-
owed  in  the  three  main  specialized  adult  centres  in  Portugal
Porto,  Coimbra  and  Lisbon)  between  January  01  and  Decem-
er  31,  2012.
All  patients  were  diagnosed  with  CF  according  to  the
iagnostic  criteria  in  their  consensus  statement.
These  patients  were  assigned  to  one  of  two  groups:  those
iagnosed  at  <18  years  old  (Group1  --  G1)  and  those  diag-
osed  at  ≥18  years  old  (Group2  --  G2).
Several  variables  were  evaluated  (demographic,  diag-
ostic,  genetic,  mortality,  health  status,  and  other  related
ariables)  after  which  the  two  groups  were  compared.
The  patients  were  analysed  into  CFTR  mutation  classes,
nd  according  to  these,  were  subdivided  into  severe  (classes
,  II  or  III)  or  mild  (patients  with  at  least  one  allele  from  class
V  to  VI).
Statistical  analysis  was  performed  using  SPSS  Statistics
9.0.
esults
ighty-nine  patients  with  CF  were  identiﬁed,  55  (61.8%)
iagnosed  at  age  <18  years  of  age  (G1)  and  34  (38.2%)  at
ge  ≥18  years  of  age  (G2).
Forty-one  patients  (46%)  were  male  and  48  (54%)  were
emale.  Gender  distribution  was  similar  in  both  groups  (G1
s.  G2:  women  54.5%  vs.  52.9%,  men  45.5%  vs.  47.1%).
The  average  age  was  31.3  ±  9.0  years.  There  were  statis-
ically  signiﬁcant  differences  in  relation  to  current  age,  and
he  average  age  of  patients  in  G2  was  older  (38.3  ±  8.4  vs.
6.8  ±  6.1  years,  p  <  0.001).
All  of  the  included  patients  were  Caucasian.
The  median  age  at  diagnosis  was  13,  and  34  (38.2%)  were
iagnosed  in  adulthood.
Over  one-half  of  adults  were  women,  yet  men  were  more
ikely  to  receive  a  late  diagnosis  (Table  1).
There  were  signiﬁcant  associations  between  age  at  diag-
osis  and  the  condition  suggesting  the  diagnosis  (respiratory
nd  digestive  symptoms),  as  noted  in  Table  2.
Although  respiratory  symptoms  (recurrent/acute  respi-
atory  infections,  cough,  haemoptysis)  were  the  mosts  V,  et  al.  Rev  Port  Pneumol.  2016.
requent  clinical  manifestations  leading  to  the  diagnosis  in
ll  patients,  this  is  particularly  evident  when  patients  are
iagnosed  as  adults  (G2  vs.  G1:  75.9%  vs.  42.6%;  p  =  0.005).
atients  in  G1  showed  a  greater  variability  in  conditions
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Table  1  Association  between  age  at  diagnosis  and  gender  in  patients  with  CF.a
Gender  Group  G1  (<18  years),  %
(n =  55)
Group  G2  (≥18  years),  %
(n =  34)
Male  (n  =  41)  61.0  39.0
Female (n  =  48) 62.5 37.5
a p-Value 0.884.
Table  2  Association  between  age  at  diagnosis  and  condition  suggesting  diagnosis.
Presentation  formsa Group  G1  (<18  years),  %
(n =  55)
Group  G2  (≥18  years),  %
(n =  34)
p-Value
Respiratory  symptoms  42.6  75.9  0.005
Digestive symptoms  44.7  17.2  0.014
Family screening 6.4 3.4 0.283
Failure  to  thrive  malnutrition  6.4  --  0.283
Infertility --  3.4  0.382
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suggesting  the  diagnosis,  and  digestive  symptoms  that  most
frequently  lead  to  diagnosis  (G1  vs.  G2:  44.7%  vs.  17.2%;
p  =  0.014).  In  G2,  3.4%  of  patients  were  diagnosed  due  to  fer-
tility  problems  and  failure  to  thrive  was  observed  only  in  G1.
Furthermore,  respiratory  symptoms  were  more  frequent  in
female  patients  (70.7%  vs.  37.1%,  p  =  0.003)  whereas  diges-
tive  symptoms  were  the  most  frequent  in  males  (54.3%  vs.
17.1%,  p  <  0.001).
All  patients  studied  were  genotyped.  The  most  frequent
mutation  identiﬁed  was  delF508  (54.9%),  27  patients  (30.3%)
were  homozygous  and  41  (46.1%)  heterozygous.  The  second
most  common  mutation  was  R334  W  (12.7%).  There  was  a
greater  percentage  of  patients  homozygous  for  the  muta-
tion  delF508  in  G1  (43.6%  vs.  8.8%,  p  =  0.02)  as  illustrated  in
Table  3.  Greater  heterogeneity  of  mutations  in  the  G2  has
been  veriﬁed;  signiﬁcantly  higher  percentages  of  patients  in
G2  were  either  heterozygous  for  delF508  or  did  not  carry  the
allele  (91.2%  vs.  56.4%,  respectively).
According  to  CFTR  mutation  classes,  40  (46.5%)  had  CFTR
mutation  classes  I,  II  or  III  (severe)  and  46  patients  (53.5%)
had  at  least  one  allele  from  classes  IV--VI  (mild).
Thirty-six  patients  (66.7%)  showed  severe  mutation
classes  in  G1,  compared  with  4  patients  (11.8%)  in  G2
(p  <  0.001).
Considering  pancreatic  function,  39  patients  (97.5%)  with
severe  CFTR  mutation  classes  presented  pancreatic  insufﬁ-Please  cite  this  article  in  press  as:  Santo
http://dx.doi.org/10.1016/j.rppnen.2016.07.002
ciency  vs.  9  patients  (19.6%)  with  mild  CFTR  mutation  classes
(p  <  0.001).
The  average  value  of  FEV1 was  58.8  ±  28.9%,  23  patients
(25.8%)  with  FEV1 >  80%  and  26  (29.2%)  <40%,  3  of  which
(
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Table  3  Association  between  genotype  delF508  and  age  at  diagn
Genotype  Group  G1  (<18  years),  %
delF508  Homozygous  43.6  
delF508 Heterozygous  40.0  
Others mutations  16.4  
a p = 0.02.20%.  The  assessment  of  respiratory  function  showed  a
igher  severity  in  G1,  with  patients  in  G2  attaining  slightly
igher  mean  percentage  predicted  of  FVC  and  FEV1 scores;
here  was  not  a  signiﬁcant  difference  in  FVC  and  FEV1 values
etween  groups  (Table  4).
Thus,  despite  being  considerably  older  (about  12  years
ifference),  the  G2  patients  presented  results  of  lung  func-
ion  tests  which  were  similar  to  the  G1.
Forty-nine  patients  (56%)  had  exocrine  pancreatic  insufﬁ-
iency  and  8  of  these  also  had  CF-related  diabetes  and  were
n  insulin  therapy.  A  higher  rate  of  pancreatic  insufﬁciency
as  found  in  G1  and  this  difference  was  signiﬁcant  (74.1%
s.  27.3%,  p  <  0.001).  Pancreatic  function  is  closely  related
o  the  genotype.  All  patients  with  delF508  homozygous  had
ancreatic  dysfunction.
The  average  value  of  body-mass-index  (BMI)  was
0.9  ±  4.1  kg/m2.  Forty-one  patients  (46.1%)  had  BMI  <  20
nd  14  (15.7%)  were  obese  (BMI  >  25).
Assessment  of  BMI  showed  a  higher  level  of  this  vari-
ble  in  G1  and  this  difference  was  statistically  signiﬁcant
20.1  ±  3.4  vs.  22.2  ±  4.8,  p  =  0.018).
In  culture  result  analysis,  lung  transplant  patients  (14)
ere  excluded  and  therefore  only  75  patients  were  con-
idered.  The  most  common  microbiological  isolates  were
seudomonas  aeruginosa  (Pa)  in  49  patients  (55.1%)  and
ethicillin-sensitive-Staphylococcus-aureus  (MSSA)  in  50s  V,  et  al.  Rev  Port  Pneumol.  2016.
56.2%).  Most  of  the  patients  had  fewer  than  three  microbio-
ogical  isolates  and  more  than  two  germs  isolated.  Regarding
ifferences  between  microbiological  isolation  and  age  at
iagnosis  (Table  4),  Pa  and  MSSA  were  the  most  frequently
osis.a
 (n  =  55)  Group  G2  (≥18  years),  %  (n  =  34)
8.8
55.9
35.3
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Table  4  Association  between  lung  function  and  microbiological  result  with  age  at  diagnosis.
Lung  function  Group  G1  (<18  years)a n  Group  G2  (≥18  years)a n  p-Value
FEV1%  predicted  54.6  (27.3)  54  65.6  (30.6)  34  0.148
FVC %  predicted  72.1  (31.3)  27  85.6  (29.2)  20  0.197
Microbiological  results Group  G1  (<18  years)b n  Group  G2  (≥18  years)b n  p-Value
Pseudomonas  aeruginosa  60.0  33  47.1  16  0.33
Burkholderia  cepacia  12.7  7  0  0.041
Methicillin-sensitive  Staphylococcus  aureus  58.2  32  52.9  18  0.792
Methicillin-resistant  Staphylococcus  aureus  20.0  11  14.7  5  0.728
Achromobacter  baumannii 7.4  2  5.0  1  1.0
Aspergillus 22.2 6  5.0 10  0.094
Nontuberculosis  mycobacterium 5.5 3  5.9 2  1.0
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sResults given as mean (SD).
b Results given as %.
solated  microorganisms  in  both  groups  (G1  vs.  G2:  Pa:
0.0%  vs.  47.1%,  p  =  0.33;  MSSA: 58.2%  vs.  52.9%,  p  =  0.792).
urkholderia  cepacia  was  isolated  only  in  G1  (12.7%  vs.  0%,
 =  0.041).
Lung  transplantation  rate  was  higher  in  G2  (G2  vs.  G1:
0.6%  vs.  12.7%,  p  =  0.490).
Fourteen-patients  were  hospitalized  for  complications.
ospital  admissions  rate  was  higher  in  G1  (G1  vs.  G2:
4.0%  vs.  17.6%,  p  =  0.148).  Two-patients  (2.2%)  died  due
o  lung  transplant  rejection  and  sepsis  of  pulmonary  ori-
in.  Mortality  rate  was  higher  in  G1  (G2  vs.  G1:  0%  vs.  3.6%,
 =  0.522).
iscussion
n  consideration  of  the  fact  that  diagnosis  of  CF  in  adult-
ood  is  possible  and  appears  to  be  increasing,26 this  study
xplored  issues  dealing  with  late  diagnosis,  with  the  objec-
ive  of  identifying  any  possible  differences  in  clinical  pre-
entation  of  CF  between  patients  diagnosed  before  and  after
8  years  of  age.
In  this  study  adults  who  received  late  diagnosis  of  CF
ave  unique  characteristics  that  suggest  particular  needs
n  terms  of  treatment  and  support;  they  experienced  fewer
omplications  and  fewer  hospital  admissions  than  those  who
eceived  diagnosis  under  18  years  of  age,  in  whom  respira-
ory  (p  =  0.148)  and  pancreatic  (p  <  0.001)  involvement  was
ess  severe  and  had  a  signiﬁcantly  better  nutritional  status
p  = 0.018).
Signiﬁcant  association  between  age  at  diagnosis  and  the
ondition  suggesting  the  diagnosis  was  found,  in  spite  of  the
act  that  respiratory  symptoms  were  the  most  frequent  man-
festations  leading  to  the  diagnosis  in  all  patients;  this  is
articularly  evident  when  the  diagnosis  is  made  in  adult-
ood.
The  study  also  found  a  greater  percentage  of  homozy-
ous  delF508  among  patients  diagnosed  earlier  in  life  than
n  those  diagnosed  in  adulthood,  and  this  difference  was  sta-Please  cite  this  article  in  press  as:  Santo
http://dx.doi.org/10.1016/j.rppnen.2016.07.002
istically  signiﬁcant.  It  is  recognized  that  homozygosity  for
elF508  mutation  is  associated  with  a  high  systemic  reper-
ussion  of  CF,  a  high  level  of  pancreatic  insufﬁciency  and
 low  BMI.  On  the  other  hand,  the  greater  heterogeneity
i
s
in  mutations  of  patients  with  a  late  diagnosis  found  in  this
tudy  could  be  responsible  for  the  greater  variance  in  con-
itions  leading  to  diagnosis  and  the  overall  better  indexes
f  health  in  this  group;  it  is  a  fact  that  patients  diagnosed  in
dulthood  had  fewer  hospitalizations  and  experience  fewer
omplications  than  those  diagnosed  early  in  life  and  most  of
hem  were  pancreatic  sufﬁcient,  which  is  closely  related  to
he  type  of  CFTR  mutation  associated.27,28
In  the  study,  as  is  common  in  the  literature,  most  of
hose  diagnosed  early  in  life  present  with  a  combination
f  gastrointestinal  and  pulmonary  symptoms,  while  in  the
ate  diagnosis  group  of  patients  most  were  diagnosed  due  to
ecurrent  pulmonary  infections  and  gastrointestinal  symp-
oms  were  less  frequent.25
The  acquisition  of  infectious  agents  is  an  important  envi-
onmental  modiﬁer  which  determines  course  and  prognosis
f  most  patients  with  CF.  Furthermore,  patients  who  are
nfected  experience  a  more  rapid  decline  of  lung  function
han  their  non-  infected  peers.29 Although  no  signiﬁcant  dif-
erence  between  age  at  diagnosis  and  culture  results  was
ound,  and  there  was  not  a  signiﬁcant  difference  in  FVC  and
EV1 values  between  groups,  there  was  a  higher  percentage
f  microbiological  isolations  in  G1  patients,  and  the  assess-
ent  of  respiratory  function  showed  a  greater  severity  in
hese  patients.
No  signiﬁcant  differences  were  found  between  groups  in
erms  of  transplantation  and  mortality  rates.
The  above  results  provide  empirical  support  that  supports
he  argument  that  patients  with  a  late  diagnosis  of  CF  are
ifferent  from  those  who  receive  early  diagnosis.
onclusions
n  summary,  this  study  is  the  ﬁrst  description  of  the  Por-
uguese  adult  CF  population  and  the  ﬁrst  to  examine  two
istinct  populations  on  the  basis  of  age  at  diagnosis,  which
s  particularly  important,  since  it  gives  us  a  better  under-
tanding  of  real  life.s  V,  et  al.  Rev  Port  Pneumol.  2016.
A signiﬁcant  percentage  of  our  patients  were  diagnosed
n  adulthood,  which  highlights  the  need  for  diagnostic
uspicion  in  a  patient  with  chronic  lung  disease  and  atyp-
cal  symptoms.  In  the  study  performed,  a  10  years  longer
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Comparison  between  patients  in  paediatric  and  adult  age  
lifetime  was  detected  in  patients  diagnosed  in  adulthood.
This  difference  may  be  associated  with  higher  frequency
of  homozygosity  for  the  mutation  delF508  found  in  patients
diagnosed  early  in  life  which  is  usually  associated  to  a  higher
systemic  repercussion  of  CF  and  a  higher  level  of  pancreatic
insufﬁciency  cases  and  lower  BMI.
The  results  suggest  that  patients  diagnosed  in  the  pae-
diatric  age  group  have  characteristics  that  distinguish  them
from  those  diagnosed  in  adulthood,  which  may  have  impli-
cations  in  terms  of  diagnosis,  prognosis  and  life  expectancy.
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